Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
A pharmacokinetic (PK)/pharmacodynamic (PD) modeling strategy to simulate in vivo bactericidal effects for three carbapenem antibiotics, doripenem (DRPM), meropenem (MEPM)/cilastatin (CS), and imipenem (IPM)/CS, against a Pseudomonas aeruginosa (P. aeruginosa) strain is proposed. The PD model we have already developed to explain in vitro time-kill profiles was modified to incorporate the growth rate, bactericidal activities, and PK profiles in murine lung infection models. Plasma concentration data and bacterial time-kill data for each antibiotic consist of six and eight time points, respectively, at one dose regimen (four or five mouse/point). In vivo time-kill curves could be well simulated for each antibiotic by the PK/PD model. Simulated bacterial counts at 24 h and PK/PD indices derived from total drug concentrations (time above the minimum inhibitory concentration (MIC) (T > MIC), C(max)/MIC, and AUC/MIC) for various dose regimens were examined for MEPM/CS and IPM/CS. Simulated bacterial counts correlated only with T > MIC (correlation coefficient: 0.951 for MEPM/CS, 0.982 for IPM/CS) and T > MIC values to achieve a bacteriostatic effect and a 2-log killing effect for both antibiotics were estimated to be approximately 15 and 20%, respectively, which are similar to previously reported results. These findings suggested that the proposed PK/PD model is a good tool for predicting in vivo bactericidal effects.
Katsube
Takayuki
T
Biostatistics Department, Shionogi & Co., Ltd., Sagisu 5-12-4, Fukushima-ku, Osaka 553-0002, Japan.
Yamano
Yoshinori
Y
Yano
Yoshitaka
Y
D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D019540:Area Under Curve; D001424:Bacterial Infections / Q000188:drug therapy*; D015780:Carbapenems / Q000493:pharmacokinetics / Q000494:pharmacology; D015377:Cilastatin / Q000493:pharmacokinetics / Q000494:pharmacology; D004195:Disease Models, Animal; D000077726:Doripenem; D005260:Female; D015378:Imipenem / Q000493:pharmacokinetics / Q000494:pharmacology; D000077731:Meropenem; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D013845:Thienamycins / Q000493:pharmacokinetics / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D000077726:Doripenem; D000077731:Meropenem